Wall Street brokerages expect Teleflex Incorporated (NYSE:TFX) to report earnings per share of $2.78 for the current quarter, according to Zacks. Six analysts have issued estimates for Teleflex’s earnings, with the highest EPS estimate coming in at $2.83 and the lowest estimate coming in at $2.74. Teleflex reported earnings per share of $2.44 in the same quarter last year, which would suggest a positive year over year growth rate of 13.9%. The company is scheduled to issue its next earnings report before the market opens on Thursday, February 28th.
On average, analysts expect that Teleflex will report full year earnings of $9.91 per share for the current financial year, with EPS estimates ranging from $9.87 to $9.97. For the next financial year, analysts expect that the firm will report earnings of $11.07 per share, with EPS estimates ranging from $10.94 to $11.27. Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side analysts that cover Teleflex.
A number of equities research analysts recently weighed in on TFX shares. Barclays started coverage on shares of Teleflex in a research note on Monday, October 15th. They set an “equal weight” rating and a $266.00 price objective on the stock. Needham & Company LLC restated a “buy” rating and set a $315.00 price objective on shares of Teleflex in a research note on Friday, November 2nd. Piper Jaffray Companies lifted their price objective on shares of Teleflex to $310.00 and gave the company an “overweight” rating in a research note on Friday, November 2nd. UBS Group started coverage on shares of Teleflex in a research note on Tuesday, November 27th. They set a “buy” rating and a $310.00 price objective on the stock. Finally, TheStreet upgraded shares of Teleflex from a “c+” rating to a “b-” rating in a research note on Wednesday, November 28th. Three analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $291.88.
In other Teleflex news, insider Thomas E. Powell sold 5,200 shares of the business’s stock in a transaction dated Friday, December 7th. The shares were sold at an average price of $259.41, for a total value of $1,348,932.00. Following the sale, the insider now directly owns 13,651 shares in the company, valued at $3,541,205.91. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Thomas E. Powell sold 5,324 shares of the business’s stock in a transaction dated Thursday, December 27th. The stock was sold at an average price of $242.25, for a total transaction of $1,289,739.00. Following the completion of the sale, the chief financial officer now owns 13,775 shares in the company, valued at $3,336,993.75. The disclosure for this sale can be found here. Over the last quarter, insiders sold 21,148 shares of company stock worth $5,273,753. 2.56% of the stock is owned by company insiders.
A number of institutional investors have recently modified their holdings of the business. BlackRock Inc. raised its position in Teleflex by 2.8% in the third quarter. BlackRock Inc. now owns 4,993,747 shares of the medical technology company’s stock worth $1,328,788,000 after acquiring an additional 135,484 shares in the last quarter. Atlanta Capital Management Co. L L C raised its holdings in Teleflex by 17.7% during the 3rd quarter. Atlanta Capital Management Co. L L C now owns 2,650,228 shares of the medical technology company’s stock worth $705,199,000 after buying an additional 399,301 shares during the period. FMR LLC raised its holdings in Teleflex by 632.5% during the 3rd quarter. FMR LLC now owns 1,343,305 shares of the medical technology company’s stock worth $357,440,000 after buying an additional 1,159,914 shares during the period. William Blair Investment Management LLC raised its holdings in Teleflex by 52.1% during the 3rd quarter. William Blair Investment Management LLC now owns 955,428 shares of the medical technology company’s stock worth $254,230,000 after buying an additional 327,451 shares during the period. Finally, Bank of New York Mellon Corp raised its holdings in Teleflex by 7.2% during the 4th quarter. Bank of New York Mellon Corp now owns 589,152 shares of the medical technology company’s stock worth $152,284,000 after buying an additional 39,748 shares during the period. Hedge funds and other institutional investors own 92.67% of the company’s stock.
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It offers vascular access products that comprise Arrow branded catheters and related devices, including catheter positioning systems for use in the administration of intravenous medications and other therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site; and devices for treating coronary and peripheral vascular disease.
Read More: Capital Gains
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.